Back to search results

Prokinetics and Body Surface Gastric Mapping for Gastroparesis and Functional Dyspepsia

This study is for people with gastroparesis or functional dyspepsia, which are stomach disorders causing symptoms like nausea and abdominal pain. Researchers are observing how a non-invasive device called Gastric Alimetry™ works alongside common medications like metoclopramide, erythromycin, nortriptyline, or mirtazapine. The Gastric Alimetry™ System measures electrical activity in your stomach. The goal is to see if this device can help doctors better understand how these medications affect your stomach's electrical rhythms over 8 weeks. You may be able to join if you are 18 or older, have one of these diagnoses, are already prescribed one of these medications, and can have the Gastric Alimetry™ test before and during treatment.

Study design
This is an observational study involving about 125 participants. It looks at how the Gastric Alimetry device measures stomach activity before and during treatment with a prokinetic agent or symptom modulator.
What's involved
You would need to undergo a Gastric Alimetry recording before starting your medication and another recording while on treatment.
Compensation
Not stated in the trial record.
Follow-up
The main measurement for this study is taken at 8 weeks after starting treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06854120

Prokinetics and Body Surface Gastric Mapping in Dyspeptic Patients: Baseline and Treatment Effects

Recruiting
Not specifiedAges 18+Observational
University of Auckland, New Zealand
~125 participants
Updated 2026-06-11 on ClinicalTrials.gov
What's tested:Gastric Alimetry

At a glance

Recruiting sites
2 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in overall postprandial BSGM Gastric Alimetry Rhythm Index (minimum: 0; maximum: 1) on treatment compared to baseline (with a lower score meaning worse outcome).
Measured over 8 weeks

Conditions

Gastroparesis
Functional Dyspepsia

Explore related trials

GastroparesisNonulcer dyspepsia

Where it's being run

3 sites across 3 states
Pennsylvania1
New South Wales1
Auckland1

Study leadership

  • Henry Parkman, MD · PRINCIPAL_INVESTIGATOR · Temple University
  • Vincent Ho, MBBS, FRACP, FACP, PhD · PRINCIPAL_INVESTIGATOR · University of Western Sydney
  • Charlotte Daker, MD · PRINCIPAL_INVESTIGATOR · University of Auckland, New Zealand
  • Greg O'Grady, MD, PhD · PRINCIPAL_INVESTIGATOR · University of Auckland, New Zealand

Who to contact

Genevieve M Johnston, PhD
[email protected]
+64 9 373 7599
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients 18 years of age and older
Diagnosis of gastroparesis and/or functional dyspepsia
Being prescribed a prokinetic agent or symptom modulator for their clinical care
Able to undergo BSGM recording both before and during treatment
Able to give informed consent for undergoing a baseline BSGM recording and an additional recording while on treatment

Exclusion

Under 18 years of age
Prior surgery on esophagus, stomach (appendectomy and cholecystectomy are allowed)
History of skin allergies or a history of extreme sensitivity to cosmetics or lotions
Pregnant women
No vulnerable groups such as prisoners, individuals with known cognitive impairment, or institutionalized individuals be involved

What this trial measures

  • Change in overall postprandial BSGM Gastric Alimetry Rhythm Index (minimum: 0; maximum: 1) on treatment compared to baseline (with a lower score meaning worse outcome).8 weeks